Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September ...

Financial Data and Key Metrics Changes - Revenue for Q2 2023 was $6 million, a 43% increase year-over-year, driven by organic growth and new product lines [7][17] - Gross profit for Q2 2023 was $4 million, a 33% increase from Q2 2022, with margins at 67% [25] - Operating loss for Q2 was $6.7 million, up from $5.9 million a year ago, but down from $7.5 million in Q1 [28] - Net loss for Q2 2023 was $5.3 million, flat compared to the same period last year [29] - Cash, cash equivalents, and available securities were over $142 million at the end of Q2 2023, down from $187 million a year ago [31] Business Line Data and Key Metrics Changes - TRUFORMA revenue increased by 98% year-over-year, driven by organic growth and new assays [20] - PulseVet products saw a 14% increase year-over-year, reflecting strong demand in the small animal veterinary market [19] - Assisi generated $1 million in incremental revenue for Q2 2023, contributing to overall growth [21] - VetGuardian product line is expected to ramp up revenue as it is introduced through various distributors [22] Market Data and Key Metrics Changes - Approximately 25% of PulseVet revenue was international at the time of acquisition, with expectations for growth in international markets [42] - The company has a wholly-owned subsidiary in Japan and distributors in Europe and South America [42] Company Strategy and Development Direction - The company is focused on achieving cash flow positivity and GAAP profitability through revenue growth and efficient manufacturing [12][15] - Strategic priorities include improving the quality of care for pets and the profitability of veterinarian customers [12] - The company is actively seeking M&A opportunities that are accretive to earnings [13][71] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing strong sales momentum and new product launches [33] - The company expects revenue to increase in subsequent periods due to expanded product lines and acquisitions [24] - Management reiterated guidance for cash flow breakeven in the second half of next year [46][47] Other Important Information - R&D expenses increased significantly due to the buildup of internal capabilities for product development [26] - The company is transitioning manufacturing to its facility in Georgia to improve margins [10] Q&A Session Summary Question: What does the company's debt to income ratio look like? - The company has no debt, only lease obligations, and is in a loss position [36][38] Question: Is the company considering a stock buyback? - The company is focused on growth and does not plan to initiate a stock buyback until achieving cash flow breakeven [41] Question: What percentage of market capitalization has been achieved in Europe? - The company is currently generating about 20% to 25% of its revenue internationally, with significant growth opportunities [42] Question: When will the company sell throughout the U.S. with salespeople? - The company has a direct sales force and is expanding its sales territories opportunistically [44] Question: Are there financing options available to help vets acquire the product? - The company has third-party financing options available for its products [64][65] Question: Why are the assays taking so long to come out? - The company has recently gained the ability to develop its own assays at its own pace, which will improve future timelines [66][67]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (St ...

Zomedica Corp. (NYSE:ZOM) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Jason Kolbert - Dawson James Operator Good afternoon, ladies and gentlemen and welcome to Zomedica’s First Quarter of 2023 Earnings Release Call. As a reminder, this call is being recorded and all participants are in a listen-only mode. The call will be open to questions and answers following the presentation. On today’s call are Zomedica’s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (S ...

Zomedica Corp. (NYSE:ZOM) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Larry Heaton - Chief Executive Officer Ann Cotter - Chief Financial Officer Paul Kuntz - Investor Relations Greg Blair - Vice President, Business Development & Strategic Planning Conference Call Participants Operator Good afternoon, and welcome to Zomedica's Fiscal Year 2022 Earnings Release Call. As a reminder, this call is being recorded and all participants are in a listen-only mode. The call will be ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38298 ZOMEDICA CORP. (Exact name of registrant as specified in its charter) Alberta, Canada ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/ ...

ZOMEDICA® "It's All In The Waves" Larry Heaton Chief Executive Officer ZOM LISTED NYSE AMERICAN 8/18/2022 Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or in the territories or possessions thereof. Prospective investors should not construe the contents of this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (St ...